Archive for the ‘Viral Genetics Inc. VRAL’ Category

Viral Genetics Inc. (VRAL.PK) is “One to Watch”

Monday, July 6th, 2009

Viral Genetics Inc. is a company that discovers and develops drug compounds to treat diseases such as cancer, Lyme disease, and HIV. The company discovers and develops immune-based therapies for autoimmune diseases using their thymus nuclear protein compound (TNP).

Viral Genetics recently entered into an Exclusive License Agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the company) to license technology developed by M. Karen Newell, PhD. This technology appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials.

Thymus Nuclear Protein (TNP) is the core of their initial approach to the development of immune-based therapies. The company’s lead product candidate is VGV-1. It is an investigational treatment for HIV/AIDS, consisting of TNP suspended in adjuvant. TNP proteins were originally studied as a means of early-detection of certain cancers.

In early pilot studies, the company learned that if the protein was introduced to an HIV-positive patient’s system along with adjuvant, over time an immuno-precipitation reaction gradually reappeared over approximately 8 weeks that was similar to an HIV-negative patient’s reaction. This was the start of their understanding the therapeutic potential of TNP. Consequently, this led directly to the company’s clinical development of VGV-1.

Viral Genetics, Inc. believes that VGV-1 represents a unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. As a type of immune-based therapy, it focuses on boosting the immune system to allow the body to fight HIV more efficiently. Five human clinical trials have studied VGV-1 for the treatment of HIV/AIDS.

In May, Viral Genetics, Inc. announced that they were issued a patent for novel cancer therapies. The patent protects cancer drugs that have been tested in pre-clinical research studies in mice. Additional patents directed at generic classes of the drugs are still pending. The new therapies use metabolic disruption as a treatment of cancers, including multi-drug resistant cancers. This process is accomplished by the administration of 2-deoxy-D-glucose to inhibit high rate glucose metabolism, characteristic of cancer cells. The administration of 2-deoxy-D-glucose can be used in combination with current, standard chemotherapeutics and/or in combination with etomoxir, an inhibitor of fatty acid oxidation.

Let us hear your thoughts: Viral Genetics Inc. Message Board

Viral Genetics, Inc. (VRAL.PK) Receives Patent for Cancer Treatment Therapies

Friday, June 19th, 2009

Viral Genetics, Inc., a company that develops drug compounds to treat cancer, Lyme Disease, and HIV, has received a patent for cancer treatment therapies. This patent protects cancer drugs that have used mice as clinical research subjects. Issued on March 31, 2009, the U.S. Patent Number is: 7,510,710.

M. Karen Newell, PhD., tenured professor at the University of Colorado, stated, “This patent represents the first method for treating drug resistant cancer using metabolic disruption, an approach targeting the distinct cancer-specific metabolic activities that can distinguish cancer cells in general, and many drug resistant cancer types, in specific, from normal cells in normal tissues.”

She continued, “We are very excited that the Patent Office has recognized the significance of work we first pioneered over eight years ago. The scientific community is now coming to accept the approach, metabolic disruption, as an extremely promising method for helping cancer patients.”

The new drug therapy uses metabolic disruption to treat varying forms of cancer. This process is designed to inhibit high rate glucose metabolism, characteristic of cancer cells. The drug therapy can be used in combination chemotherapy and/or in combination with etomoxir, an inhibitor of fatty acid oxidation. Drug resistant tumor cells commonly use fatty acid metabolism to meet their distinct energy requirements. Disrupting these metabolic pathways can cause death of the cancer cells without significant adverse effect on non-cancer cells.

This treatment specifically addresses patients who do not respond to chemotherapy and radiation. The growing popularity of chemotherapy drug “cocktails” has given rise to multidrug resistant tumor cells that are even more difficult to destroy. Although both treatments destroy a significant number of tumor cells, a small number remains, which can grow into a new, treatment resistant tumor. With each round of chemotherapy, the proportion of drug resistant cells to drug sensitive cells increases. Eventually, the cancer becomes increasingly difficult to treat.

“Drug resistance, either acquired or inherent, is the leading cause of death in cancer, a disease that kills at least 6.2 million people worldwide annually,” said Viral Genetics CEO Haig Keledjian. “Our new therapy takes aim at that process.”

Let us hear your thoughts below:

Dutton Associates Featured Company: Viral Genetics Inc. (VRAL.PK)

Tuesday, June 3rd, 2008

Viral Genetics Inc. is a biotechnology company with a focus on protein-based therapeutic and diagnostic products with applications in infectious disease, autoimmune conditions, and immunological deficiency. The company and its management team are key players in the fight against HIV/AIDS, infectious disease, and autoimmune deficiency. Viral Genetics has been working since 1995 to find a cure for HIV/AIDS and is based in Azusa, California.

VRAL develops its products based on thymus nuclear protein (TNP), a processed extract of mammalian thymus tissue. It has developed a lead product, VGV-1, which is a suspension of TNP in alum adjuvant for the treatment of HIV infection and AIDS. VGV-1 is currently in the preclinical stage of development in the United States, but outside of the USA it is in later stage development. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment.

Over the past 13 years, Viral Genetics has performed five human clinical trials in South Africa, China, Bulgaria, and Mexico utilizing VGV-1, and each time the results have suggested a significant decrease in the HIV viral load. The HIV market has historically had high growth rates because of the desperate need for a cure. According to the World Health Organization’s annual report in 2007, the number of people infected with HIV or AIDS globally had reached 33.2 million. With such a desperate need for a cure, companies like Viral Genetics are vital to the global market as the anticipation for a cure to this epidemic grows by the day.

Let us hear your thoughts: Viral Genetics Inc. Message Board